StockData
Passage BIO, Inc. logo

Passage BIO, Inc. (PASG) stock

PASGNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30
$4.22+0.09 (+2.18%)

Close on Nov 17, 2026Market cap $13.58MP/E –Yield –

Passage BIO operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Passage BIO's operating income for the twelve months ending Jun 30, 2026 was -$39.02M. For fiscal 2025 it was -$49.30M. The highest annual figure on record is -$37.19M in fiscal 2019.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$49.30M–
FY2024Dec 31, 2024-$70.40M–
FY2023Dec 31, 2023-$108.39M–
FY2022Dec 31, 2022-$138.39M–
FY2021Dec 31, 2021-$185.73M–
FY2020Dec 31, 2020-$112.90M–
FY2019Dec 31, 2019-$37.19M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$8.27M–
Q1 FY2026Mar 31, 2026-$8.25M–
Q4 FY2025Dec 31, 2025-$13.85M–
Q3 FY2025Sep 30, 2025-$8.66M–
Q2 FY2025Jun 30, 2025-$10.33M–
Q1 FY2025Mar 31, 2025-$16.46M–
Q4 FY2024Dec 31, 2024-$14.27M–
Q3 FY2024Sep 30, 2024-$20.70M–
Q2 FY2024Jun 30, 2024-$17.38M–
Q1 FY2024Mar 31, 2024-$18.05M–
Q4 FY2023Dec 31, 2023-$18.45M–
Q3 FY2023Sep 30, 2023-$28.67M–
Q2 FY2023Jun 30, 2023-$25.39M–
Q1 FY2023Mar 31, 2023-$35.88M–
Q4 FY2022Dec 31, 2022-$28.24M–
Q3 FY2022Sep 30, 2022-$27.53M–
Q2 FY2022Jun 30, 2022-$39.81M–
Q1 FY2022Mar 31, 2022-$42.81M–
Q4 FY2021Dec 31, 2021-$51.16M–
Q3 FY2021Sep 30, 2021-$47.10M–
Q2 FY2021Jun 30, 2021-$48.53M–
Q1 FY2021Mar 31, 2021-$38.93M–
Q4 FY2020Dec 31, 2020-$39.06M–
Q3 FY2020Sep 30, 2020-$28.63M–
Q2 FY2020Jun 30, 2020-$27.30M–
Q1 FY2020Mar 31, 2020-$17.91M–
Q4 FY2019Dec 31, 2019-$13.59M–
Q3 FY2019Sep 30, 2019-$11.64M–
Q2 FY2019Jun 30, 2019-$7.77M–

More Passage BIO figures

See a number that looks wrong?